 |
Register Now! 
|
Program Description
This series of CME-certified webinars will provide community oncologists with evidence-based treatment approaches for patients with renal cell carcinoma (RCC), discuss how to evaluate treatment options to minimize adverse events, and identify how best to incorporate them in their daily practice.
The treatment of patients with advanced RCC presents significant challenges for the community oncologist. Outcomes in advanced RCC are poor, with 5-year survival rates of only 10%. Fortunately, treatment options have expanded in recent years with the approval of three targeted agents since 2006, and others showing activity in clinical trials. Although targeted therapies have been shown to prolong survival, no single agent confers durable complete responses, and patients eventually develop disease progression.
The optimal second-line therapy following disease progression on first-line therapy remains largely undefined. Sequential therapy is an area of intense investigation, and recent and ongoing clinical trials are investigating the feasibility of various targeted agents in the second-line setting. Combinations of targeted agents are also being evaluated, although issues that have arisen with some combination strategies include enhanced toxicity and at times a lack of additional benefit.
The effective incorporation of targeted agents into clinical practice presents significant challenges. The demonstrated efficacy of targeted agents has made them the new standard of care for advanced RCC. However, the optimal use of these agents, including the use of sequential and combination strategies, and the proper selection of patients for different therapies, has yet to be fully defined.
The older age of patients at diagnosis and the association between RCC and smoking and obesity contribute to comorbidities that can complicate patient care. Targeted therapies also present unique management challenges regarding treatment adherence and toxicities. Given this myriad of challenges, community oncology nurses will benefit from expert guidance on the management of side effects, and other recommendations regarding the optimal care of patients with advanced RCC.
Based on current and rapidly evolving management strategies in advanced RCC and the educational needs of community-based healthcare providers, RCCTrends: Bringing Targeted Therapy to Community Oncology Practice webinar series has been developed as an interactive resource to healthcare providers who wish to access information that tracks the progress of clinical research and evolving treatment strategies for patients with RCC.
The RCCTrends webinar series will be convened in May and June 2009 as three, 1-hour live evening webinars and then available as web-based on-demand archives from the Kidney Cancer Association (www.kidneycancer.org). Each live webinar will be hosted by oncology experts who will review evidence-based strategies that focus on
Target Audience
This activity has been designed for community oncologists and nurses who provide care and support to patients with advanced RCC.
Learning Objectives
As a result of participating in the activity, participants will be able to
Activity Director
Robert A. Figlin, MD
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and Therapeutics Research
City of Hope National Medical Center and Beckman Research Institute
Associate Director for Clinical Research
City of Hope National Medical Center
Duarte, California
Faculty
Gary R. Hudes, MD
Director, Genitourinary Malignancies Program
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Nancy P. Moldawer, RN, MSN
Clinical Research Operations Manager
Acting Director, Clinical Trials Office
Department of Medical Oncology and Experimental Therapeutics
City of Hope National Medical Center
Duarte, California
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
The City of Hope designates this educational activity for 3 AMA Physicians’ Recognition Award™ credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
The City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational is provided below.
Robert A. Figlin, MD (Activity Director)
Gary R. Hudes, MD
Nancy P. Moldawer RN, MSN
Independent Clinical Peer Reviewer
Robert J. Morgan Jr., MD
Director, Continuing Medical Education
Associate Director for Education
Department of Oncology and Therapeutics Research
City of Hope National Medical Center
Duarte, California
Planning Committee
Crystal Saavedra, City of Hope National Medical Center, and Deborah Dean, Mindy Tanzola, PhD, and Michelle Yechout, Alliance Medical Communications: No relevant financial relationships with any commercial interests.
Information discussed by faculty regarding off-label or investigational use of products not FDA-approved will be included with the release of each webinar.
Core Competencies
The American Board of Medical Specialties and the Accreditation Council of Graduate Medical Education have embarked on a joint initiative to quantify and evaluate a set of six physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification. Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission of Healthcare Organizations on their practice and demonstration of the six core competencies.
In brief, “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: 1) Patient Care, 2) Medical Knowledge, 3) Practice-based Learning, 4) Interpersonal and Communication Skills, 5) Professionalism and 6) Systems-based Practice. More details about each competency are included below.
All educational content presented will have been reviewed by the program directors. To assist participants in demonstrating their completion of continuing medical education in the 6 core competencies, we asked each presenter to indicate for which of the core competencies will the educational content of their presentation provide information or insight. Presentations may address more than one. Responses are listed in the table immediately following this section.
1) Patient Care that is compassionate, appropriate, and effective for the treatment of health problems and the promotion of health
2) Medical Knowledge about established and evolving biomedical, clinical, and cognate (e.g. epidemiological and social-behavioral) sciences and the application of this knowledge to patient care
3) Practice-Based Learning and Improvement that involves investigation and evaluation of their own patient care, appraisal and assimilation of scientific evidence, and improvements in patient care
4) Interpersonal and Communication Skills that result in effective information exchange and teaming with patients, their families, and other health professionals
5) Professionalism, as manifested through a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to a diverse patient population
6) Systems-Based Practice, as manifested by actions that demonstrate an awareness of and responsiveness to the larger context and system of health care and the ability to effectively call on system resources to provide care that is of optimal value
Cultural Diversity
The California legislature has passed AB 1195 which states that as of July 1, 2006 all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component.
If there is relevant cultural diversity information relating to age, gender, race, socio-economics, sexual orientation, religion, language, ethnicity, etc. that impacts the care of the patient, faculty are required to include it in his/her presentation. All members of the faculty reported there is no cultural diversity and patient care data within his/her presentation.
This series of CME-certified webinars will provide community oncologists with evidence-based treatment approaches for patients with renal cell carcinoma (RCC), discuss how to evaluate treatment options to minimize adverse events, and identify how best to incorporate them in their daily practice.
The treatment of patients with advanced RCC presents significant challenges for the community oncologist. Outcomes in advanced RCC are poor, with 5-year survival rates of only 10%. Fortunately, treatment options have expanded in recent years with the approval of three targeted agents since 2006, and others showing activity in clinical trials. Although targeted therapies have been shown to prolong survival, no single agent confers durable complete responses, and patients eventually develop disease progression.
The optimal second-line therapy following disease progression on first-line therapy remains largely undefined. Sequential therapy is an area of intense investigation, and recent and ongoing clinical trials are investigating the feasibility of various targeted agents in the second-line setting. Combinations of targeted agents are also being evaluated, although issues that have arisen with some combination strategies include enhanced toxicity and at times a lack of additional benefit.
The effective incorporation of targeted agents into clinical practice presents significant challenges. The demonstrated efficacy of targeted agents has made them the new standard of care for advanced RCC. However, the optimal use of these agents, including the use of sequential and combination strategies, and the proper selection of patients for different therapies, has yet to be fully defined.
The older age of patients at diagnosis and the association between RCC and smoking and obesity contribute to comorbidities that can complicate patient care. Targeted therapies also present unique management challenges regarding treatment adherence and toxicities. Given this myriad of challenges, community oncology nurses will benefit from expert guidance on the management of side effects, and other recommendations regarding the optimal care of patients with advanced RCC.
Based on current and rapidly evolving management strategies in advanced RCC and the educational needs of community-based healthcare providers, RCCTrends: Bringing Targeted Therapy to Community Oncology Practice webinar series has been developed as an interactive resource to healthcare providers who wish to access information that tracks the progress of clinical research and evolving treatment strategies for patients with RCC.
The RCCTrends webinar series will be convened in May and June 2009 as three, 1-hour live evening webinars and then available as web-based on-demand archives from the Kidney Cancer Association (www.kidneycancer.org). Each live webinar will be hosted by oncology experts who will review evidence-based strategies that focus on
| • | Clinical trial results for available agents in advanced RCC |
| • | How to best incorporate immunotherapy and targeted agents into practice |
| • | How to improve the care of patients with advanced RCC through proactive side effect management, patient/caregiver education, and supportive care strategies |
Target Audience
This activity has been designed for community oncologists and nurses who provide care and support to patients with advanced RCC.
Learning Objectives
As a result of participating in the activity, participants will be able to
| • | Describe the strengths and limitations associated with available agents for the treatment of advanced RCC | |
| • | Compare and contrast treatment approaches and available agents which have demonstrated a clinical benefit | |
| • | Develop a plan to proactively manage adverse events in patients receiving treatment for advanced RCC | |
| • | Develop a practice plan to incorporate supportive care strategies in practice to maximize adherence and treatment effectiveness |
Activity Director
Robert A. Figlin, MD
Arthur and Rosalie Kaplan Chair in Oncology
Professor and Chair, Medical Oncology and Therapeutics Research
City of Hope National Medical Center and Beckman Research Institute
Associate Director for Clinical Research
City of Hope National Medical Center
Duarte, California
Faculty
Gary R. Hudes, MD
Director, Genitourinary Malignancies Program
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Nancy P. Moldawer, RN, MSN
Clinical Research Operations Manager
Acting Director, Clinical Trials Office
Department of Medical Oncology and Experimental Therapeutics
City of Hope National Medical Center
Duarte, California
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the City of Hope and Alliance Medical Communications. The City of Hope is accredited by the ACCME to provide continuing medical education for physicians.
Designation of Credit
The City of Hope designates this educational activity for 3 AMA Physicians’ Recognition Award™ credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Disclosure
The City of Hope takes responsibility for the content, quality and scientific integrity of this continuing medical education (CME) activity. Prior to their participation in this City of Hope CME activity, all faculty/presenters have disclosed any real or apparent vested commercial interest(s) in both those companies whose products may be discussed during the course of the activity and in those companies acting as commercial supporters of the activity. City of Hope further requires that prior to the activity, faculty/presenters have disclosed their intention to discuss any off-label and/or investigational (not yet approved for any purpose) use of pharmaceuticals or medical devices. Written disclosure of faculty/presenters’ specific commercial relationships and/or intent to discuss off-label and/or investigational is provided below.
Robert A. Figlin, MD (Activity Director)
| Commercial Interest | Relationship |
| Aveo Pharmaceuticals | Consultant |
| Amgen, Argos Therapeutics, Antisoma plc, Novartis AG; Pfizer Inc |
Grant/Research Support |
Gary R. Hudes, MD
| Commercial Interest | Relationship |
| Genentech; Novartis AG; Pfizer Inc; Wyeth | Consultant |
| Pfizer Inc | Speakers’ Bureau |
Nancy P. Moldawer RN, MSN
| Commercial Interest | Relationship |
| Novartis AG; Pfizer Inc; Wyeth | Speakers’ Bureau |
Independent Clinical Peer Reviewer
Robert J. Morgan Jr., MD
Director, Continuing Medical Education
Associate Director for Education
Department of Oncology and Therapeutics Research
City of Hope National Medical Center
Duarte, California
Planning Committee
Crystal Saavedra, City of Hope National Medical Center, and Deborah Dean, Mindy Tanzola, PhD, and Michelle Yechout, Alliance Medical Communications: No relevant financial relationships with any commercial interests.
Information discussed by faculty regarding off-label or investigational use of products not FDA-approved will be included with the release of each webinar.
Core Competencies
The American Board of Medical Specialties and the Accreditation Council of Graduate Medical Education have embarked on a joint initiative to quantify and evaluate a set of six physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification. Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission of Healthcare Organizations on their practice and demonstration of the six core competencies.
In brief, “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: 1) Patient Care, 2) Medical Knowledge, 3) Practice-based Learning, 4) Interpersonal and Communication Skills, 5) Professionalism and 6) Systems-based Practice. More details about each competency are included below.
All educational content presented will have been reviewed by the program directors. To assist participants in demonstrating their completion of continuing medical education in the 6 core competencies, we asked each presenter to indicate for which of the core competencies will the educational content of their presentation provide information or insight. Presentations may address more than one. Responses are listed in the table immediately following this section.
1) Patient Care that is compassionate, appropriate, and effective for the treatment of health problems and the promotion of health
2) Medical Knowledge about established and evolving biomedical, clinical, and cognate (e.g. epidemiological and social-behavioral) sciences and the application of this knowledge to patient care
3) Practice-Based Learning and Improvement that involves investigation and evaluation of their own patient care, appraisal and assimilation of scientific evidence, and improvements in patient care
4) Interpersonal and Communication Skills that result in effective information exchange and teaming with patients, their families, and other health professionals
5) Professionalism, as manifested through a commitment to carrying out professional responsibilities, adherence to ethical principles, and sensitivity to a diverse patient population
6) Systems-Based Practice, as manifested by actions that demonstrate an awareness of and responsiveness to the larger context and system of health care and the ability to effectively call on system resources to provide care that is of optimal value
| Faculty | Core Competency addressed by presentation |
| Robert A. Figlin, MD | 2-6 |
| Gary R. Hudes, MD | 1-3 |
| Nancy P. Moldawer, RN, MSN | 1–6 |
Cultural Diversity
The California legislature has passed AB 1195 which states that as of July 1, 2006 all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component.
| DEFINITIONS: | Cultural competency means a set of integrated attitudes, knowledge, and skills that enables a health care professional or organization to care effectively for patients from diverse cultures, groups, and communities. Linguistic competency means the ability of a physician and surgeon to provide patients who do not speak English or who have limited ability to speak English, direct communication in the patient's primary language. |
If there is relevant cultural diversity information relating to age, gender, race, socio-economics, sexual orientation, religion, language, ethnicity, etc. that impacts the care of the patient, faculty are required to include it in his/her presentation. All members of the faculty reported there is no cultural diversity and patient care data within his/her presentation.